These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 18044689)

  • 1. Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients.
    Dal NR; Eandi M; Pradelli L; Iannazzo S
    Int J Chron Obstruct Pulmon Dis; 2007; 2(2):169-76. PubMed ID: 18044689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma.
    Johansson G; Andreasson EB; Larsson PE; Vogelmeier CF
    Pharmacoeconomics; 2006; 24(7):695-708. PubMed ID: 16802845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
    Roberts M; Mapel D; Petersen H; Blanchette C; Ramachandran S
    J Med Econ; 2011; 14(6):769-76. PubMed ID: 21942463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone.
    Löfdahl CG; Ericsson A; Svensson K; Andreasson E
    Pharmacoeconomics; 2005; 23(4):365-75. PubMed ID: 15853436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma.
    Gerzeli S; Rognoni C; Quaglini S; Cavallo MC; Cremonesi G; Papi A
    Clin Drug Investig; 2012 Apr; 32(4):253-65. PubMed ID: 22352412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma.
    Miller E; Sears MR; McIvor A; Liovas A
    Can Respir J; 2007; 14(5):269-75. PubMed ID: 17703241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients.
    Dalal AA; St Charles M; Petersen HV; Roberts MH; Blanchette CM; Manavi-Zieverink K
    Int J Chron Obstruct Pulmon Dis; 2010 Aug; 5():179-87. PubMed ID: 20714371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
    Spencer M; Briggs AH; Grossman RF; Rance L
    Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluations.
    Anthonisen NR
    Can Respir J; 2007; 14(5):264-6. PubMed ID: 17874484
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
    Frois C; Wu EQ; Ray S; Colice GL
    Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies - a Canadian economic evaluation.
    Miller E; FitzGerald JM
    Can J Clin Pharmacol; 2008; 15(2):e165-76. PubMed ID: 18515918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries.
    Nielsen R; Kankaanranta H; Bjermer L; Lange P; Arnetorp S; Hedegaard M; Stenling A; Mittmann N
    Respir Med; 2013 Nov; 107(11):1709-21. PubMed ID: 23856511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study.
    Roggeri A; Micheletto C; Roggeri DP
    Int J Chron Obstruct Pulmon Dis; 2014; 9():569-76. PubMed ID: 24940053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
    Perrone V; Sangiorgi D; Buda S; Degli Esposti L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
    Hertel N; Kotchie RW; Samyshkin Y; Radford M; Humphreys S; Jameson K
    Int J Chron Obstruct Pulmon Dis; 2012; 7():183-99. PubMed ID: 22500119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled salmeterol/fluticasone propionate: a review of its use in asthma.
    Reynolds NA; Lyseng-Williamson KA; Wiseman LR
    Drugs; 2005; 65(12):1715-34. PubMed ID: 16060707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
    Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
    J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
    Blais L; Forget A; Ramachandran S
    Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease.
    Nannini L; Lasserson TJ; Poole P
    Cochrane Database Syst Rev; 2003; (4):CD003794. PubMed ID: 14583994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial.
    Ismaila AS; Birk R; Shah D; Zhang S; Brealey N; Risebrough NA; Tabberer M; Zhu CQ; Lipson DA
    Adv Ther; 2017 Sep; 34(9):2163-2172. PubMed ID: 28875459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.